# Preclinical development of a novel therapeutic for Parkinson's disease

> **NIH NIH R44** · SINOPIA BIOSCIENCES, INC. · 2024 · $1,282,299

## Abstract

Project Summary
Parkinson’s Disease (PD) is the second most common neurodegenerative disorder, afflicting ~1 million
Americans. Levodopa is the gold-standard symptomatic treatment for PD by elevating dopamine levels in the
brain. Though the most effective treatment, prolonged levodopa use leads to 1) the debilitating side effect,
levodopa-induced dyskinesia (LID), and 2) diminished levodopa efficacy which leads to fluctuations of PD
symptoms, known as “wearing-off”. These concerns are two of the greatest unmet needs in PD and affect how
doctors prescribe dosages and treatment options, impacting the efficacy of the necessary medications for PD.
After 5 years of levodopa usage, 40% of PD patients will develop LID and/or fluctuations. Not only having a
clinical impact, but PD patients with such complications require nearly $60,000 of additional therapeutics every
year. Using Sinopia Biosciences’ computational platform, we studied gene expression changes due to
levodopa administered to 6-OHDA lesioned PD-like mice. Applying our computational workflow, we identified a
small molecule (SB-0107) that was selected based on: 1) having one of the top scores from our platform, 2) its
novel mechanism of action, 3) previous clinical exposure to elderly patients, 4) its predicted CNS penetration
properties, and 5) its potential for patent protection. Subsequently, we demonstrated the compound’s unique
and potentially transformative pharmacology for treating both the symptoms of PD and complications of
levodopa (i.e. LID). In both rodent and primate models, SB-0107 shows large effect sizes. Further, we
observed in a cognitive deficit primate model of PD that SB-0107 improves performances in the tested
cognitive tasks. Thus, SB-0107 represents a promising candidate for advancement to the clinic for PD. In this
Fast-Track proposal, we will advance the compound by completing preclinical development studies for
anticipation of IND submission.

## Key facts

- **NIH application ID:** 10812364
- **Project number:** 5R44NS124398-03
- **Recipient organization:** SINOPIA BIOSCIENCES, INC.
- **Principal Investigator:** Aarash Bordbar
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,282,299
- **Award type:** 5
- **Project period:** 2021-09-30 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10812364

## Citation

> US National Institutes of Health, RePORTER application 10812364, Preclinical development of a novel therapeutic for Parkinson's disease (5R44NS124398-03). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10812364. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*